Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

safety

25th Feb 2026

Long-term outcomes of atacicept therapy in IgA nephropathy patients: a plain language summary

28th Oct 2025

Plain language summary of adult Lyme disease vaccine booster trial

18th Jul 2025

Plain language summary: research findings on eptinezumab for migraine prevention in patients who didn’t respond to previous treatments

23rd Apr 2025

Plain language summary of safety data on the BNT162b2 COVID-19 vaccine: development, approval and ongoing monitoring

15th Nov 2024

Plain language summary: safety analysis of futibatinib across different cancer types

6th Sep 2024

A plain-language summary of two 5-Year studies on bictegravir/emtricitabine/tenofovir alafenamide in people with HIV

Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer that has spread within or beyond the kidney. Axitinib has been approved for the treatment of RCC as either a first treatment option or a second treatment option. It is used as a first treatment option for RCC when combined with a medication that reactivates the immune system (immunotherapy), either avelumab or pembrolizumab. If the advanced RCC starts growing again it can be used as a second treatment option where it is taken by itself. It is essential to conduct studies to assess how well the drug works and whether it has any side effects in order to understand whether it is safe to give to people.
1st Aug 2023

Plain Language Summary: looking at how long side effects last after stopping axitinib treatment in people with advanced renal cell carcinoma

18th Jul 2022

Once-nightly sodium oxybate (FT218) improved symptoms in people with narcolepsy: a plain language summary of publication

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy